Intermediate-term efficacy of Tm:YAG laser prostate vaporesection for bladder outlet obstruction: initial experience from a UK teaching hospital.
Urol Int
; 88(1): 39-42, 2012.
Article
in En
| MEDLINE
| ID: mdl-22133639
ABSTRACT
OBJECTIVES:
To assess the safety and clinical efficacy of TmYAG laser vaporesection of the prostate (ThuVaRP) at intermediate-term follow-up. PATIENTS ANDMETHODS:
We identified the first 60 consecutive patients who underwent ThuVaRP at our institute. Operative outcomes assessed were resection time, resection weight, drop in haemoglobin, transfusion rate, catheter time and complication rate. The International Prostate Symptom Score (IPSS) was documented at a mean follow-up period of 19 months postoperatively.RESULTS:
45/60 patients underwent treatment due to lower urinary tract symptoms secondary to benign prostatic obstruction, 11/60 patients had a long-term catheter in situ for refractory urinary retention secondary to benign prostatic obstruction, and 4/60 patients had bladder outflow obstruction secondary to adenocarcinoma of the prostate. 1/60 patients developed urosepsis, 1/60 patients developed a urinary tract infection and 1/60 patients required 3-way catheterization and irrigation due to haematuria. No patients required a blood transfusion. The mean IPSS at a mean follow-up interval of 19 months (range 15-28 months) was 5.1 (range 1-23). Postoperative maximum flow rate improved from 7.9 to 17.1 ml/s, and post-micturition residual volume decreased from 254 to 86 ml.CONCLUSION:
ThuVaRP is safe and appears to have durable efficacy at intermediate follow-up.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostate
/
Prostatic Hyperplasia
/
Prostatic Neoplasms
/
Thulium
/
Urinary Bladder Neck Obstruction
/
Adenocarcinoma
/
Laser Therapy
/
Lasers, Solid-State
Type of study:
Etiology_studies
/
Prognostic_studies
Limits:
Humans
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
Urol Int
Year:
2012
Document type:
Article